Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Nonsyndromic craniosynostosis: novel coding variants.

Sewda A, White SR, Erazo M, Hao K, García-Fructuoso G, Fernández-Rodriguez I, Heuzé Y, Richtsmeier JT, Romitti PA, Reva B, Jabs EW, Peter I.

Pediatr Res. 2019 Mar;85(4):463-468. doi: 10.1038/s41390-019-0274-2. Epub 2019 Jan 14.

2.

Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy.

Martignetti JA, Pandya D, Nagarsheth N, Chen Y, Camacho O, Tomita S, Brodman M, Ascher-Walsh C, Kolev V, Cohen S, Harkins TT, Schadt EE, Reva B, Sebra R, Dottino P.

Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003269. doi: 10.1101/mcs.a003269. Print 2018 Dec.

3.

Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas.

Wang H, Bender A, Wang P, Karakose E, Inabnet WB, Libutti SK, Arnold A, Lambertini L, Stang M, Chen H, Kasai Y, Mahajan M, Kinoshita Y, Fernandez-Ranvier G, Becker TC, Takane KK, Walker LA, Saul S, Chen R, Scott DK, Ferrer J, Antipin Y, Donovan M, Uzilov AV, Reva B, Schadt EE, Losic B, Argmann C, Stewart AF.

Nat Commun. 2017 Oct 3;8(1):767. doi: 10.1038/s41467-017-00992-9.

4.

Accuracy of cervical cytology: comparison of diagnoses of 100 Pap smears read by four pathologists at three hospitals in Norway.

Sørbye SW, Suhrke P, Revå BW, Berland J, Maurseth RJ, Al-Shibli K.

BMC Clin Pathol. 2017 Aug 29;17:18. doi: 10.1186/s12907-017-0058-8. eCollection 2017.

5.

Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.

Nair N, Camacho-Vanegas O, Rykunov D, Dashkoff M, Camacho SC, Schumacher CA, Irish JC, Harkins TT, Freeman E, Garcia I, Pereira E, Kendall S, Belfer R, Kalir T, Sebra R, Reva B, Dottino P, Martignetti JA.

PLoS Med. 2016 Dec 27;13(12):e1002206. doi: 10.1371/journal.pmed.1002206. eCollection 2016 Dec.

6.

Development and clinical application of an integrative genomic approach to personalized cancer therapy.

Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl AS, Davis C, Lau CY, Pandya C, Shah H, Kasai Y, Powell J, Micchelli M, Castellanos R, Zhang Z, Linderman M, Kinoshita Y, Zweig M, Raustad K, Cheung K, Castillo D, Wooten M, Bourzgui I, Newman LC, Deikus G, Mathew B, Zhu J, Glicksberg BS, Moe AS, Liao J, Edelmann L, Dudley JT, Maki RG, Kasarskis A, Holcombe RF, Mahajan M, Hao K, Reva B, Longtine J, Starcevic D, Sebra R, Donovan MJ, Li S, Schadt EE, Chen R.

Genome Med. 2016 Jun 1;8(1):62. doi: 10.1186/s13073-016-0313-0.

7.

A new molecular signature method for prediction of driver cancer pathways from transcriptional data.

Rykunov D, Beckmann ND, Li H, Uzilov A, Schadt EE, Reva B.

Nucleic Acids Res. 2016 Jun 20;44(11):e110. doi: 10.1093/nar/gkw269. Epub 2016 Apr 20.

8.

Mutation Screening of Candidate Genes in Patients with Nonsyndromic Sagittal Craniosynostosis.

Ye X, Guilmatre A, Reva B, Peter I, Heuzé Y, Richtsmeier JT, Fox DJ, Goedken RJ, Jabs EW, Romitti PA.

Plast Reconstr Surg. 2016 Mar;137(3):952-61. doi: 10.1097/01.prs.0000479978.75545.ee.

9.

Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21(∗) in SCC progression.

Ge Y, Zhang L, Nikolova M, Reva B, Fuchs E.

Nat Cell Biol. 2016 Jan;18(1):111-21. doi: 10.1038/ncb3275. Epub 2015 Nov 30.

10.

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

Hellmann MD, Reva B, Yu H, Rusch VW, Rizvi NA, Kris MG, Arcila ME.

J Thorac Oncol. 2014 Oct;9(10):e73-4. doi: 10.1097/JTO.0000000000000221. No abstract available.

11.

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M.

Clin Cancer Res. 2015 Apr 15;21(8):1935-43. doi: 10.1158/1078-0432.CCR-14-2124. Epub 2014 Oct 28.

12.

Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.

Rendleman J, Antipin Y, Reva B, Adaniel C, Przybylo JA, Dutra-Clarke A, Hansen N, Heguy A, Huberman K, Borsu L, Paltiel O, Ben-Yehuda D, Brown JR, Freedman AS, Sander C, Zelenetz A, Klein RJ, Shao Y, Lacher M, Vijai J, Offit K, Kirchhoff T.

PLoS One. 2014 Jul 10;9(7):e101685. doi: 10.1371/journal.pone.0101685. eCollection 2014.

13.

Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.

Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B, Fuchs E.

Science. 2014 Jan 17;343(6168):309-13. doi: 10.1126/science.1248627.

14.

Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles.

Rekhtman N, Borsu L, Reva B, Arcila M, Riely GJ, Ladanyi M, Drilon A.

J Thorac Oncol. 2014 Jan;9(1):e1-3. doi: 10.1097/JTO.0b013e3182a471c3. No abstract available.

15.

Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.

Hamilton MP, Rajapakshe K, Hartig SM, Reva B, McLellan MD, Kandoth C, Ding L, Zack TI, Gunaratne PH, Wheeler DA, Coarfa C, McGuire SE.

Nat Commun. 2013;4:2730. doi: 10.1038/ncomms3730.

16.

The molecular diversity of Luminal A breast tumors.

Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N.

Breast Cancer Res Treat. 2013 Oct;141(3):409-20. doi: 10.1007/s10549-013-2699-3. Epub 2013 Oct 6.

17.

Computational approaches to identify functional genetic variants in cancer genomes.

Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GR, Creixell P, Karchin R, Vazquez M, Fink JL, Kassahn KS, Pearson JV, Bader GD, Boutros PC, Muthuswamy L, Ouellette BF, Reimand J, Linding R, Shibata T, Valencia A, Butler A, Dronov S, Flicek P, Shannon NB, Carter H, Ding L, Sander C, Stuart JM, Stein LD, Lopez-Bigas N; International Cancer Genome Consortium Mutation Pathways and Consequences Subgroup of the Bioinformatics Analyses Working Group.

Nat Methods. 2013 Aug;10(8):723-9. doi: 10.1038/nmeth.2562.

18.
19.

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.

Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, Hsieh JJ; ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators.

Clin Cancer Res. 2013 Jun 15;19(12):3259-67. doi: 10.1158/1078-0432.CCR-12-3886. Epub 2013 Apr 25.

20.

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M.

Mol Cancer Ther. 2013 Feb;12(2):220-9. doi: 10.1158/1535-7163.MCT-12-0620. Epub 2013 Jan 31.

21.

Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells.

Asai T, Liu Y, Di Giandomenico S, Bae N, Ndiaye-Lobry D, Deblasio A, Menendez S, Antipin Y, Reva B, Wevrick R, Nimer SD.

Blood. 2012 Aug 23;120(8):1601-12. doi: 10.1182/blood-2011-11-393983. Epub 2012 Jul 9.

22.

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N.

Cancer Discov. 2012 May;2(5):401-4. doi: 10.1158/2159-8290.CD-12-0095. Erratum in: Cancer Discov. 2012 Oct;2(10):960.

23.

Predicting the functional impact of protein mutations: application to cancer genomics.

Reva B, Antipin Y, Sander C.

Nucleic Acids Res. 2011 Sep 1;39(17):e118. doi: 10.1093/nar/gkr407. Epub 2011 Jul 3.

24.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M.

Nat Genet. 2011 Jun 5;43(7):668-72. doi: 10.1038/ng.855.

25.

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S.

Nat Genet. 2010 Aug;42(8):715-21. doi: 10.1038/ng.619. Epub 2010 Jul 4.

26.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

27.

p53 regulates hematopoietic stem cell quiescence.

Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD.

Cell Stem Cell. 2009 Jan 9;4(1):37-48. doi: 10.1016/j.stem.2008.11.006.

28.

A specificity map for the PDZ domain family.

Tonikian R, Zhang Y, Sazinsky SL, Currell B, Yeh JH, Reva B, Held HA, Appleton BA, Evangelista M, Wu Y, Xin X, Chan AC, Seshagiri S, Lasky LA, Sander C, Boone C, Bader GD, Sidhu SS.

PLoS Biol. 2008 Sep 30;6(9):e239. doi: 10.1371/journal.pbio.0060239.

29.
30.

Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.

Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, Shah S, Vanderbeek G, Coit D, Busam K, Halpern A, Houghton A, Sander C, Berwick M, Orlow I.

BMC Med Genet. 2007 Mar 8;8:10.

32.

Determining the roles of different chain fragments in recognition of immunoglobulin fold.

Reva B, Kister A, Topiol S, Gelfand I.

Protein Eng. 2002 Jan;15(1):13-9.

PMID:
11842233
33.

Derivation and testing residue-residue mean-force potentials for use in protein structure recognition.

Reva BA, Finkelstein AV, Skolnick J.

Methods Mol Biol. 2000;143:155-74. No abstract available.

PMID:
11084906
35.

[When and how can homologs overcome errors in the energy estimates and make the 3D structure prediction possible].

Finkel'shteĭn AV, Rykunov DS, Lobanov MIu, Badretdinov FIa, Reva BA, Skolnick J, Mirnyĭ LA, Shakhnovich EI.

Biofizika. 1999 Nov-Dec;44(6):980-91. Russian.

PMID:
10707272
36.

Averaging interaction energies over homologs improves protein fold recognition in gapless threading.

Reva BA, Skolnick J, Finkelstein AV.

Proteins. 1999 May 15;35(3):353-9.

PMID:
10328270
37.

Optimization of protein structure on lattices using a self-consistent field approach.

Reva BA, Rykunov DS, Finkelstein AV, Skolnick J.

J Comput Biol. 1998 Fall;5(3):531-8.

PMID:
9773348
38.

What is the probability of a chance prediction of a protein structure with an rmsd of 6 A?

Reva BA, Finkelstein AV, Skolnick J.

Fold Des. 1998;3(2):141-7.

PMID:
9565758
39.

Recognition of protein structure on coarse lattices with residue-residue energy functions.

Reva BA, Finkelstein AV, Sanner M, Olson AJ, Skolnick J.

Protein Eng. 1997 Oct;10(10):1123-30.

PMID:
9488137
40.

Residue-residue mean-force potentials for protein structure recognition.

Reva BA, Finkelstein AV, Sanner MF, Olson AJ.

Protein Eng. 1997 Aug;10(8):865-76.

PMID:
9415437
41.

Accurate mean-force pairwise-residue potentials for discrimination of protein folds.

Reva BA, Finkelstein AV, Sanner MF, Olson AJ.

Pac Symp Biocomput. 1997:373-84.

42.

Building self-avoiding lattice models of proteins using a self-consistent field optimization.

Reva BA, Finkelstein AV, Rykunov DS, Olson AJ.

Proteins. 1996 Sep;26(1):1-8.

PMID:
8880925
43.

Adjusting potential energy functions for lattice models of chain molecules.

Reva BA, Finkelstein AV, Sanner MF, Olson AJ.

Proteins. 1996 Jul;25(3):379-88.

PMID:
8844872
46.

Accurate general method for lattice approximation of three-dimensional structure of a chain molecule.

Rykunov DS, Reva BA, Finkelstein AV.

Proteins. 1995 Jun;22(2):100-9.

PMID:
7567958
47.

Constructing lattice models of protein chains with side groups.

Reva BA, Rykunov DS, Olson AJ, Finkelstein AV.

J Comput Biol. 1995 Winter;2(4):527-35.

PMID:
8634904
48.
49.

[A rapid and precise method for lattice approximation of the course of a protein chain based on a dynamic programming algorithm].

Rykunov DS, Reva BA, Finkel'shteĭn AV.

Mol Biol (Mosk). 1994 Jul-Aug;28(4):855-64. Russian.

PMID:
7990814
50.

Supplemental Content

Support Center